Page last updated: 2024-08-21

fluorobenzenes and Muscle Disorders

fluorobenzenes has been researched along with Muscle Disorders in 34 studies

Research

Studies (34)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (70.59)	29.6817
2010's	10 (29.41)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barratt, BJ; Chasman, DI; Danik, JS; MacFadyen, JG; Nyberg, F; Ridker, PM	1
Drobny, M; Odalos, I; Pullmann, R; Saniova, B; Skerenova, M	1
Dorajoo, Rs; Gopalakrishnakone, P; Lee, E; Leong, CC; Pereira, BP; Wee, A; Yu, Z	1
Kapur, NK; Musunuru, K	1
Danielson, E; Fonseca, FA; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Ridker, PM; Shepherd, J; Willerson, JT	1
Smith, M; Sullivan, D; Wlodarczyk, J	1
de Carvalho, M; Evangelista, T; Ferro, J; Pereira, P	1
Abel, T; Fehér, J	1
Azuma, CT; Marsden, AM; Orton, TC; Scott, RC; Sidaway, J; Wang, Y; Westwood, FR	1
Genest, J; Glynn, RJ; Hsia, J; MacFadyen, JG; Mora, S; Ridker, PM	1
García Rodríguez, LA; Herings, R; Johansson, S	1
Auteri, A; Ciani, F; Puccetti, L; Scarpini, F	1
Al-Salameh, A; Bihan, H; Cohen, R; Dhote, R; Keller-Petrot, I; Reach, G	1
Cutchins, C; Cutchins, DC; Gopalagowda, BH; Peiris, AN	1
Hu, M; Mak, VW; Tomlinson, B	1
Barber, GR; Barron, MA; Golightly, LK; Page, RL	1
Bolognese, MA; Caplan, R; Cressman, M; Hutchinson, H; Raza, A; Schwartz, GG; Tremblay, BP	1
Wolfe, SM	1
Davidson, MH	1
Finsterer, J; Stöllberger, C	1
McKenney, JM	1
Goettsch, WG; Heintjes, EM; Herings, RM; Johansson, S; Kastelein, JJ; Rabelink, TJ	1
Cutone, JA; Danielson, JD; Fox, JC; McAfee, AT; Ming, EE; Ng, EW; Quinn, SG; Seeger, JD; Walker, AM	1
Dedon, PC; Gilman, S; Glassock, RJ; Gogolak, V; Gordis, L; Guengerich, FP; Muñoz, A; Wasserman, SI; Witztum, JL; Wogan, GN; Zipes, DP; Zvaifler, NJ	1
Guthrie, RM	1
Aurich-Barrera, B; Cornelius, V; Kasliwal, R; Shakir, SA; Wilton, LV	1
Dedhia, V; Munsi, SC	1
Bar, SL; Frohlich, J; Holmes, DT	1
Bigley, A; Marsden, AM; Randall, K; Scott, RC; Westwood, FR	1
García-Rodríguez, LA; González-Pérez, A; Johansson, S; Stang, MR; Wallander, MA	1
García-Rodríguez, LA; Johansson, S; Massó-González, EL; Wallander, MA	1

Reviews

8 review(s) available for fluorobenzenes and Muscle Disorders

Article	Year
Clinical efficacy and safety of statins in managing cardiovascular risk. Vascular health and risk management, 2008, Volume: 4, Issue:2 Topics: Atherosclerosis; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Muscular Diseases; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2008
Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. The American journal of cardiology, 2008, Dec-15, Volume: 102, Issue:12 Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides	2008
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUP Circulation, 2010, Mar-09, Volume: 121, Issue:9 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Comorbidity; Double-Blind Method; Dyslipidemias; Early Termination of Clinical Trials; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Risk; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides; Treatment Outcome	2010
Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:12 Topics: Acute Kidney Injury; Chemical and Drug Induced Liver Injury; Databases, Factual; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; International Cooperation; Male; Middle Aged; Muscular Diseases; Pharmacoepidemiology; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2010
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert opinion on drug safety, 2004, Volume: 3, Issue:6 Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Biomarkers; Cholesterol, LDL; Creatine Kinase; Creatine Kinase, MM Form; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Isoenzymes; Kidney Tubules; Muscular Diseases; Product Surveillance, Postmarketing; Proteinuria; Pyridines; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides	2004
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
Rosuvastatin: an independent analysis of risks and benefits. MedGenMed : Medscape general medicine, 2006, Jun-14, Volume: 8, Issue:2 Topics: Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Muscular Diseases; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides	2006
How safe is aggressive statin therapy? Progress in cardiovascular nursing, 2006,Summer, Volume: 21, Issue:3 Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006

Trials

5 trial(s) available for fluorobenzenes and Muscle Disorders

Article	Year
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. American heart journal, 2013, Volume: 165, Issue:6 Topics: Alleles; Cardiovascular Diseases; DNA; Double-Blind Method; Fluorobenzenes; Follow-Up Studies; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Primary Prevention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2013
Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture. Neuro endocrinology letters, 2014, Volume: 35, Issue:2 Topics: Aged; Electromyography; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Male; Middle Aged; Muscular Diseases; Polymorphism, Genetic; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides	2014
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine, 2008, Nov-20, Volume: 359, Issue:21 Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides	2008
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUP Circulation, 2010, Mar-09, Volume: 121, Issue:9 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Comorbidity; Double-Blind Method; Dyslipidemias; Early Termination of Clinical Trials; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Risk; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides; Treatment Outcome	2010
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. American heart journal, 2004, Volume: 148, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2004

Other Studies

22 other study(ies) available for fluorobenzenes and Muscle Disorders

Article	Year
Role of multi-drug resistance-associated protein-1 transporter in statin-induced myopathy. Life sciences, 2008, Apr-09, Volume: 82, Issue:15-16 Topics: Animals; Body Weight; Electron Transport Complex IV; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron, Transmission; Mitochondria, Muscle; Multidrug Resistance-Associated Proteins; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Paraffin Embedding; Probenecid; Pyrimidines; Rats; Rats, Sprague-Dawley; Renal Agents; Rosuvastatin Calcium; Sulfonamides	2008
A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin. Neuromuscular disorders : NMD, 2009, Volume: 19, Issue:1 Topics: Aged; Biopsy; Creatine Kinase; Cytoplasm; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inclusion Bodies; Male; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Necrosis; Pain; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
[Statin therapy and muscle disorders]. Orvosi hetilap, 2009, Feb-08, Volume: 150, Issue:6 Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica; the fate of foreign compounds in biological systems, 2009, Volume: 39, Issue:1 Topics: Animals; Disease Models, Animal; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscle, Skeletal; Muscular Diseases; Pyridines; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
New analysis supports expanded use of statins in women. Harvard women's health watch, 2010, Volume: 17, Issue:8 Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Middle Aged; Muscular Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States; Women's Health	2010
Genetics of the coenzyme Q10 pathway and rosuvastatin-induced muscle effects. The Journal of pediatrics, 2011, Volume: 158, Issue:3 Topics: Child; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Muscular Diseases; Polymorphism, Genetic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ubiquinone	2011
Statins should be used with greater caution in patients undergoing thyroid hormone withdrawal for radioactive iodine treatment. Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:4 Topics: Compartment Syndromes; Contraindications; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iodine Radioisotopes; Muscular Diseases; Pyrimidines; Rosuvastatin Calcium; Substance Withdrawal Syndrome; Sulfonamides; Thyroid Hormones	2011
Alternate day rosuvastatin, an underutilized option in statin intolerant hyperlipidemic patients: a case report and literature review. Tennessee medicine : journal of the Tennessee Medical Association, 2011, Volume: 104, Issue:2 Topics: Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Muscular Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenetics and genomics, 2012, Volume: 22, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Asian People; Cholesterol, LDL; Female; Fluorobenzenes; Genetic Variation; Humans; Hyperlipidemias; Introns; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug metabolism and drug interactions, 2013, Volume: 28, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Creatine Kinase; Daptomycin; Drug Interactions; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Young Adult	2013
Dangers of rosuvastatin identified before and after FDA approval. Lancet (London, England), 2004, Jun-26, Volume: 363, Issue:9427 Topics: Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pyrimidines; Renal Insufficiency; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration	2004
Myalgia, hyper-CK-aemia, and hypocoagulability in a patient under rosuvastatin and warfarin. European journal of neurology, 2005, Volume: 12, Issue:8 Topics: Anticoagulants; Choline Kinase; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pleurodynia, Epidemic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Warfarin	2005
Using Crestor--and all statins--safely. Some simple steps can help minimize or avoid muscle problems from these cholesterol-lowering drugs. Harvard heart letter : from Harvard Medical School, 2005, Volume: 16, Issue:1 Topics: Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pain; Pyridines; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2005
Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiology and drug safety, 2006, Volume: 15, Issue:7 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Middle Aged; Muscular Diseases; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides	2006
The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiology and drug safety, 2006, Volume: 15, Issue:7 Topics: Adolescent; Adult; Aged; Cohort Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver; Male; Middle Aged; Muscular Diseases; Pyrimidines; Retrospective Studies; Rhabdomyolysis; Rosuvastatin Calcium; Safety; Sulfonamides	2006
Atorvastatin for stroke prevention. The Medical letter on drugs and therapeutics, 2006, Sep-11, Volume: 48, Issue:1243 Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors	2006
Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients. Drug safety, 2007, Volume: 30, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cohort Studies; Dose-Response Relationship, Drug; Drug Prescriptions; England; Family Practice; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Liver Function Tests; Male; Middle Aged; Muscular Diseases; Product Surveillance, Postmarketing; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Time Factors	2007
Myopathy caused by a combination rosuvastatin and fenofibrate. The Journal of the Association of Physicians of India, 2007, Volume: 55 Topics: Aged; Coronary Artery Disease; Drug Interactions; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Muscular Diseases; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides	2007
Asymptomatic hypothyroidism and statin-induced myopathy. Canadian family physician Medecin de famille canadien, 2007, Volume: 53, Issue:3 Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypothyroidism; Male; Middle Aged; Muscular Diseases; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Thyroid Function Tests; Thyrotropin	2007
Rosuvastatin: characterization of induced myopathy in the rat. Toxicologic pathology, 2008, Volume: 36, Issue:2 Topics: Administration, Oral; Animals; Biomarkers; Body Weight; Creatine Kinase; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Muscular Diseases; Necrosis; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Time Factors	2008
The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Saskatchewan; Sulfonamides; Young Adult	2008
The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Middle Aged; Muscular Diseases; Primary Health Care; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides; United Kingdom; Young Adult	2008